Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Onyx Pharmaceuticals, Inc. (ONXX), Amgen, Inc. (AMGN): Will This Biotech Bidding War Lead You to Larger Gains?

Page 1 of 2
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) added 3% to its one-month 60% gains on Monday because of continued speculation of a buyout. Reportedly, four companies are prepping bids to acquire Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX). What is a fair price for the company, and should you buy now?

Why the Interest?

If $120 a share significantly undervalues the company, according to Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX), then what is a fair price? This question can only be answered when you understand the fundamental upside of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX). The company is an oncology-focused drug developer with three total FDA approved drugs.

Nexavar is used to treat common forms of kidney and liver cancer. Investors anticipate Nexavar’s approval in thyroid cancer as well, after it slowed the progression of the disease compared to placebo in a Phase 3 trial. Nexavar has peak sales potential of $1.2 billion and is co-marketed with Bayer.

Bayer and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) also market a colorectal cancer drug called Stivarga, but Onyx receives just 20% of net sales. The peak sales are estimated at only $500 million, but if the drug is successful in treating liver cancer, its sales could rise to more than $1 billion.

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) markets its multiple myeloma drug Kyprolis alone. Canaccord estimates that peak sales of this drug could reach $2.1 billion by 2020, an outlook consistent with other analysts’ views.

Onyx could earn peak revenue of nearly $3 billion with these three drugs. Since Onyx’s pipeline is rather small, the company’s upside is tied to the upside of these three drugs. According to Deutsche Bank analyst Robyn Karnauskas, “you’ve probably missed the boat” in regards to Onyx. The analyst downgraded the stock from buy to hold with a $140 (buyout) price target — but is he right?

Who’s in the Running?

There are a lot of companies reportedly attempting to acquire Onyx: Amgen, Inc. (NASDAQ:AMGN), Pfizer Inc. (NYSE:PFE), Novartis, and AstraZeneca plc (ADR) (NYSE:AZN).

Amgen, Inc. (NASDAQ:AMGN) made the initial $120 offer that Onyx rejected. Therefore, Amgen, Inc. (NASDAQ:AMGN) is the only company with any action in the Onyx sweepstakes, and Amgen, Inc. (NASDAQ:AMGN) really needs Onyx. Amgen, Inc. (NASDAQ:AMGN) lacks growth, and Onyx could give Amgen, Inc. (NASDAQ:AMGN) this growth driver. Moreover, Onyx would make Amgen, Inc. (NASDAQ:AMGN) an instant leader in treating both blood-based and solid tumor cancers.
Pfizer Inc. (NYSE:PFE) is believed to be in the Onyx sweepstakes because of its competing products. Pfizer Inc. (NYSE:PFE)’s renal cancer drug Sutant has fallen short of revenue expectations during the last three quarters, and Onyx’s Nexavar is Sutant’s main rival.

While Pfizer Inc. (NYSE:PFE) is presumed to have interest because of Nexavar, I think the deal is unlikely. The renal cancer space itself is getting congested, with six targeted drugs in the space. Pfizer Inc. (NYSE:PFE)’s drug Inlyta also competes with Onyx’s Nexvar. Therefore, I don’t see what Onyx has that Pfizer Inc. (NYSE:PFE) wants. Pfizer Inc. (NYSE:PFE) already has a presence in all of Onyx’s markets.

Novartis AG (ADR) (NYSE:NVS) has reportedly been interested in acquiring Onyx for the last three years, yet has not. Novartis AG (ADR) (NYSE:NVS) was probed about the possibility of acquiring Onyx on its earnings conference call last week. Unsurprisingly, Novartis wouldn’t disclose its interest. However, speculators believe that Novartis AG (ADR) (NYSE:NVS) is seeking growth through acquisitions, and with Novartis’ cancer drug presence and their lack of growth, they finally might be interested in acquiring Onyx.
Page 1 of 2
Loading Comments...